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INTRODUCTION
Cancer cells undergo fundamental changes in their metabolism to support rapid growth, adapt to limited nutrient resources, and compete for these supplies with surrounding normal cells. One of the metabolic hallmarks of cancer is the activation of glycolysis and lactate production even in the presence of adequate oxygen. This is termed the Warburg effect, and efforts in cancer biology have revealed some of the molecular mechanisms responsible for this phenotype (Cairns et al., 2011) . More recently, 13 C isotopic studies have elucidated the complementary switch of glutamine metabolism that supports efficient carbon utilization for anabolism and growth (DeBerardinis and Cheng, 2010) . Acetyl-CoA is a central biosynthetic precursor for lipid synthesis, being generated from glucose-derived citrate in well-oxygenated cells (Hatzivassiliou et al., 2005) . Warburg-like cells, and those exposed to hypoxia, divert glucose to lactate, raising the question of how the tricarboxylic acid (TCA) cycle is supplied with acetyl-CoA to support lipogenesis. We and others demonstrated, using 13 C isotopic tracers, that cells under hypoxic conditions or defective mitochondria primarily utilize glutamine to generate citrate and lipids through reductive carboxylation (RC) of α-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) (Filipp et al., 2012; Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011) .
The transcription factors hypoxia inducible factors 1α and 2α (HIF-1α, HIF-2α) have been established as master regulators of the hypoxic program and tumor phenotype (Gordan and Simon, 2007; Semenza, 2010) . In addition to tumor-associated hypoxia, HIF can be directly activated by cancer-associated mutations. The von Hippel-Lindau (VHL) tumor suppressor is inactivated in the majority of sporadic clear-cell renal carcinomas (RCC), with VHLdeficient RCC cells exhibiting constitutive HIF-1α and/or HIF-2α activity irrespective of oxygen availability (Kim and Kaelin, 2003) . Previously, we showed that VHL-deficient cells also relied on RC for lipid synthesis even under normoxia. Moreover, metabolic profiling of two isogenic clones that differ in pVHL expression (WT8 and PRC3) suggested that reintroduction of wild-type VHL can restore glucose utilization for lipogenesis (Metallo et al., 2012) . The VHL tumor suppressor protein (pVHL) has been reported to have several functions other than the well-studied targeting of HIF. Specifically, it has been reported that pVHL regulates the large subunit of RNA polymerase (Pol) II (Mikhaylova et al., 2008) , p53 (Roe et al., 2006) , and the Wnt signaling regulator Jade-1. VHL has also been implicated in regulation of NF-κB signaling, tubulin polymerization, cilia biogenesis, and proper assembly of extracellular fibronectin (Chitalia et al., 2008; Kim and Kaelin, 2003; Ohh et al., 1998; Thoma et al., 2007; Yang et al., 2007) . Hypoxia inactivates the α-ketoglutaratedependent HIF prolyl hydroxylases, leading to stabilization of HIF. In addition to this wellestablished function, oxygen tension regulates a larger family of α-ketoglutarate-dependent cellular oxygenases, leading to posttranslational modification of several substrates, among which are chromatin modifiers (Melvin and Rocha, 2012) . It is therefore conceivable that the effect of hypoxia on RC that was reported previously may be mediated by signaling mechanisms independent of the disruption of the pVHL-HIF interaction. Here we (1) demonstrate that HIF is necessary and sufficient for RC, (2) provide insights into the molecular mechanisms that link HIF to RC, (3) detected RC activity in vivo in human VHLdeficient RCC cells growing as tumors in nude mice, (4) provide evidence that the reductive phenotype of VHL-deficient cells renders them sensitive to glutamine restriction in vitro, and (5) show that inhibition of glutaminase suppresses growth of VHL-deficient cells in nude mice. These observations lay the ground for metabolism-based therapeutic strategies for targeting HIF-driven tumors (such as RCC) and possibly the hypoxic compartment of solid tumors in general.
RESULTS

Functional Interaction between pVHL and HIF Is Necessary to Inhibit RC
To test whether the inhibition of RC by pVHL requires its ability to bind and inactivate the alpha regulatory subunit of HIF, we tested a panel of VHL germline mutations that are linked to different clinical phenotypes of the VHL disease and differ in their affinity to bind HIF. Missense germline type 2A VHL mutations confer a low risk for RCC to their carrier individuals and retain an attenuated HIF binding and regulatory activity. In contrast, type 2B mutations, which are defective in HIF binding and regulation, confer a high risk for RCC. On the other hand, type 2C VHL germline mutations are associated with an increased risk of pheochromocytomas, but not RCC, and they retain the ability to bind and inactivate HIF in a manner similar to wild-type protein, an observation that suggests that type 2C mutations inactivate HIF-independent function(s) of pVHL (Li et al., 2007) .
We infected VHL-deficient human UMRC2 renal carcinoma cells with retroviruses and generated polyclonal cell populations expressing wild-type pVHL or type 2A (Y112H), type 2B (Y98N, Y112N), and type 2C (L188V) pVHL mutants. First, we confirmed that expression of HIF-1α/HIF-2α and their downstream target GLUT1 were downregulated in cells expressing wild-type pVHL or type 2C mutant protein ( Figure 1A ). The effect of type 2A pVHL mutations appeared intermediate between wild-type and type 2B mutations regarding GLUT1 ( Figure 1A , GLUT1 lane).
To profile the metabolic phenotype of the engineered cell lines, we labeled the cells with either [U 13 -C 6 ]glucose or [1-13 C 1 ]glutamine and determined the incorporation of each tracer in TCA cycle metabolites using gas chromatography-mass spectrometry (GC-MS) ( Figure  1B ). Reintroduction of wild-type pVHL or type 2C pVHL mutant suppressed the contribution of reductive carboxylation from glutamine ( Figure 1C) , as determined by the degree of labeled carbon (M1 enrichment) of the indicated metabolites (see Figure 1B , green circles). Conversely, type 2B mutants (Y112N/Y98N, which are defective in HIF inactivation) exhibited active RC to a level comparable to VHL-deficient control cells. We observed a concurrent regulation in glucose metabolism in the different VHL mutants. Reintroduction of wild-type or type 2C pVHL mutant, which can meditate HIF-α destruction, stimulated glucose oxidation via pyruvate dehydrogenase (PDH), as determined by the degree of 13 C-labeled TCA cycle metabolites (M2 enrichment) ( Figures 1D and 1E ). In contrast, reintroduction of an HIF nonbinding Type 2B pVHL mutant failed to stimulate glucose oxidation, resembling the phenotype observed in VHL-deficient cells (Figures 1D and 1E) . Additional evidence for the overall glucose utilization was obtained from the enrichment of M3 isotopomers using [U 13 -C 6 ]glucose ( Figure S1A ), which shows a lower contribution of glucose-derived carbons to the TCA cycle in VHL-deficient RCC cells (via pyruvate carboxylase and/or continued TCA cycling).
To test the effect of HIF activation on the overall glutamine incorporation in the TCA cycle, we labeled an isogenic pair of VHL-deficient and VHL-reconstituted UMRC2 cells with [U-13 C 5 ]glutamine, which generates M4 fumarate, M4 malate, M4 aspartate, and M4 citrate isotopomers through glutamine oxidation. As seen in Figure S1B Next, to determine the specific contribution from glucose oxidation or glutamine reduction to lipogenic acetyl-CoA, we performed isotopomer spectral analysis (ISA) of palmitate labeling patterns. ISA indicates that wild-type pVHL or pVHL L188V mutant-reconstituted UMRC2 cells relied mainly on glucose oxidation to produce lipogenic acetyl-CoA, while UMRC2 cells reconstituted with a pVHL mutant defective in HIF inactivation (Y112N or Y98N) primarily employed RC. Upon disruption of the pVHL-HIF interaction, glutamine becomes the preferred substrate for lipogenesis, supplying 70%-80% of the lipogenic acetyl-CoA ( Figure 2C ). This is not a cell-line-specific phenomenon, but it applies to VHLdeficient human RCC cells in general; the same changes are observed in 786-O cells reconstituted with wild-type pVHL or mutant pVHL or infected with vector only as control ( Figure S2 ). Type 2A pVHL mutants (Y112H, which retain partial HIF binding) confer an intermediate reductive phenotype between wild-type VHL (which inactivates HIF) and type 2B pVHL mutants (which are totally defective in HIF regulation) as seen in Figures 1 and 2 . Taken together, these data demonstrate that the ability of pVHL to regulate reductive carboxylation and lipogenesis from glutamine tracks genetically with its ability to bind and degrade HIF, at least in RCC cells.
HIF Is Sufficient to Induce RC from Glutamine in RCC Cells
To test the hypothesis that HIF-2α is sufficient to promote RC from glutamine, we expressed a pVHL-insensitive HIF-2α mutant (HIF-2α P405A/P531A, marked as HIF-2α P-A) in VHL-reconstituted 786-O cells (Figure 3 ). HIF-2α P-A is constitutively expressed in this polyclonal cell population, despite the reintroduction of wild-type VHL, reflecting a pseudohypoxia condition ( Figure 3A ). We confirmed that this mutant is transcriptionally active by assaying for the expression of its targets genes GLUT1, LDHA, HK1, EGLN, HIG2, and VEGF (Figures 3B and S3A) . As shown in Figure 3C , reintroduction of wildtype VHL into 786-O cells suppressed RC, whereas the expression of the constitutively active HIF-2α mutant was sufficient to stimulate this reaction, restoring the M1 enrichment of TCA cycle metabolites observed in VHL-deficient 786-O cells. Expression of HIF-2α P-A also led to a concomitant decrease in glucose oxidation, corroborating the metabolic alterations observed in glutamine metabolism ( Figures 3D and 3E ). Additional evidence of the HIF2α-regulation on the reductive phenotype was obtained with [U-13 C 5 ]glutamine, which generates M5 citrate, M3 fumarate, M3 malate, and M3 aspartate through RC ( Figure  3F ).
Next, we tested whether VHL-independent HIF-2α expression was sufficient not only to stimulate RC in the TCA cycle but also to switch the substrate preference for lipogenesis from glucose to glutamine. Expression of HIF-2α P-A in 786-O cells phenocopied the lossof-VHL with regards to glutamine reduction for lipogenesis ( Figure 3G ), suggesting that HIF-2α can induce the glutamine-to-lipid pathway in RCC cells per se. Although reintroduction of wild-type VHL restored glucose oxidation in UMRC2 and UMRC3 cells ( Figures S3B-S3I ), HIF-2α P-A expression did not measurably affect the contribution of each substrate to the TCA cycle or lipid synthesis in these RCC cells (data not shown). UMRC2 and UMRC3 cells endogenously express both HIF-1α and HIF-2α, whereas 786-O cells exclusively express HIF-2α. There is compelling evidence suggesting, at least in RCC cells, that HIF-α isoforms have overlapping-but also distinct-functions and their roles in regulating bioenergetic processes remain an area of active investigation. Overall, HIF-1α has an antiproliferative effect, and its expression in vitro leads to rapid death of RCC cells while HIF-2α promotes tumor growth (Keith et al., 2011; Raval et al., 2005) . Because of this, we were not able to stably express the HIF-1α P-A mutant in cells that endogenously express HIF-2α only. To get insights into the role of HIF-α paralogs in promoting RC, we used mouse neonatal epithelial kidney (NEK) cells and selectively induced the expression of mouse HIF-1α or HIF-2α P-A in normoxia. Expressing HIF-1α P-A activated RC, consistent with our observation in cancer cell lines. In this model, HIF-2α P-A did not affect the contribution of this reaction to any of the TCA cycle metabolites, at least in the condition studied ( Figure S3J ). Thus, it is possible that the induction of RC by HIF-1α or HIF-2α is species-or cell-type-specific. Alternatively, there may be a redundant role of the paralogs, and/or one may adapt the control of the metabolic program in the absence of the other paralog.
Metabolic Flux Analysis Shows Net Reversion of the IDH Flux upon HIF Activation
To determine absolute fluxes in RCC cells, we employed 13 C metabolic flux analysis (MFA) as previously described (Metallo et al., 2012) . Herein, we performed MFA using a combined model of [U-13 C 6 ]glucose and [1-13 C 1 ]glutamine tracer data sets from the 786-O derived isogenic clones PRC3 (VHL −/ − )/WT8 (VHL + ) cells, which show a robust metabolic regulation by reintroduction of pVHL. To this end, we first determined specific glucose/ glutamine consumption and lactate/glutamate secretion rates. As expected, PRC3 exhibited increased glucose consumption and lactate production when compared to WT8 counterparts ( Figure 4A ). While PRC3 exhibited both higher glutamine consumption and glutamate production rates than WT8 (Figure 4A ), the net carbon influx was higher in PRC3 cells ( Figure 4B) . Importantly, the fitted data show that the flux of citrate to α-ketoglutarate was negative in PRC3 cells ( Figure 4C ). This indicates that the net (forward plus reverse) flux of isocitrate dehydrogenase and aconitase (IDH + ACO) is toward citrate production. The exchange flux was also higher in PRC3 than WT8 cells, whereas the PDH flux was lower in PRC3 cells. In agreement with the tracer data, these MFA results strongly suggest that the reverse IDH + ACO fluxes surpass the forward flux in VHL-deficient cells. The estimated ATP citrate lyase (ACLY) flux was also lower in PRC3 than in WT8 cells. Furthermore, the malate dehydrogenase (MDH) flux was negative, reflecting a net conversion of oxaloacetate into malate in VHL-deficient cells ( Figure 4C ). This indicates an increased flux through the reductive pathway downstream of IDH, ACO, and ACLY. Additionally, some TCA cycle flux estimates downstream of α-ketoglutarate were not significantly different between PRC and WT8 (Table S1 ). This shows that VHL-deficient cells maintain glutamine oxidation while upregulating reductive carboxylation ( Figure S1B ). This finding is in agreement with the higher glutamine uptake observed in VHL-deficient cells. Table S1 shows the metabolic network and complete MFA results. Similar MFA results were obtained in VHL-deficient vector versus VHL-reconstituted UMRC2 cells (data not shown). Together, the MFA data show that HIF expression reverses the net IDH flux, perhaps to compensate for a deficient citrate production due to inhibition of PDH.
HIF Activation Promotes RC by Lowering Citrate Levels
In support of the existing literature, our MFA data showed that HIF inhibits the absolute pyruvate dehydrogenase (PDH) flux Papandreou et al., 2006) . We observed that citrate levels were depleted in VHL-deficient UMRC2 cells ( Figure 5A ), with the citrate-to-α-ketoglutarate ratio being equally decreased in the VHL-deficient and HIF-2α P-A-expressing RCC cell lines ( Figures 5B and S4A ). We hypothesized that low citrate levels are key in promoting RC through mass action. To test if the mechanism by which HIF promotes RC lies in its ability to reduce citrate levels, we restored the intracellular pools of citrate, hoping to suppress RC in the TCA cycle. First, we knocked down the HIF target PDK-1 ( Figure 5C ) and observed a decreased contribution of RC to the TCA cycle in VHLdeficient PRC3 cells ( Figure 5D ). Similarly, knocking down the ATP citrate lyase enzyme ( Figure 5E ) inhibited RC in PRC3 cells (relative contribution of RC in Figure 5F , total contribution of RC in Figure S4B ). Next, we labeled VHL-deficient and VHL-reconstituted UMRC2 cells with [1-13 C 1 ]glutamine and supplemented the medium with 1 mM and 4 mM acetate. Addition of acetate decreased the relative ( Figure 5G ) and total contribution ( Figure  5H ) of RC in VHL-deficient cells, with minimal effects observed in the VHL-reconstituted counterparts. The M1 enrichment informs on RC for the formation of TCA cycle metabolites. The absence of a major effect of acetate on the minimal RC of VHLreconstituted cells is consistent with the observation that addition of acetate to these cells did not increase the intracellular citrate levels significantly ( Figures 5I and S4C) . In contrast, addition of acetate to VHL-deficient cells led to a significant increase in their citrate levels ( Figures 5I and S4C) (to a level similar to the one observed in VHL-positive cells) as well as significant inhibition of RC. To pinpoint the metabolic route of the acetate-to-citrate flux, we labeled the control and ACLY knockdown PRC3 cells with [U-13 C 2 ]acetate and observed an increased percentage of M2 citrate under ACLY knockdown conditions ( Figure S4D ), suggesting that the acetate rescue of citrate levels in VHL-deficient cells probably occurs through condensation with oxaloacetate via citrate synthase rather than through the reversibility of ACLY. We confirmed that acetate can serve as a lipogenic source in the pair of PRC3/WT8 cells ( Figure S4E ). We also cultured PRC3/WT8 cells with [5-13 C 1 ]glutamine in the presence of naturally labeled acetate. In line with the previous observations, the contribution of glutamine reduction to lipogenic acetyl-CoA was decreased under the presence of acetate ( Figure S4F ). Next, we directly supplemented the medium with citrate and rinsed the cells thoroughly with PBS before extraction to ensure measurement of the intracellular metabolite. Addition of 8 mM citrate decreased the M1 enrichment of citrate in VHL-deficient UMRC2 cells to half but, in contrast to acetate, did have a moderate effect on the minimal RC observed in VHL-reconstituted cells ( Figure 5J ). Interestingly the level of M1 fumarate, M1 aspartate, and M1 malate were unaffected. One could expect the addition of nonlabeled citrate to decrease, by definition, the percent enrichment of M1 citrate, regardless of its putative effect on RC. To control for this effect of exogenous citrate on the total formation of RC-derived citrate, we labeled the cells with [1-13 C 1 ]glutamine and [U-13 C 6 ]citrate and subtracted the total M6 citrate ions (which are exogenous and not metabolically generated by the cell) from the total citrate ions and calculated the total contribution of RC using the formula % M1 × (total ions − % M6 × total ions). Likewise, exogenous citrate significantly decreased the total contribution of RC in the VHL-deficient UMRC2 cells but also had a moderate effect in the RC observed in VHLreconstituted cells ( Figure 5K ). This differential effect between acetate and citrate on RC is consistent with and supports our hypothesis that endogenous citrate levels regulate RC by mass action. Addition of citrate in the medium, in contrast to acetate, led to an increase in the citrate-to-α-ketoglutarate ratio ( Figure 5L ) and absolute citrate levels ( Figure S4H ) not only in VHL-deficient but also VHL-reconstituted cells. The ability of exogenous citrate, but not acetate, to also affect RC in VHL-reconstituted cells may be explained by compartmentalization differences or by allosteric inhibition of citrate synthase (Lehninger, 2005) ; that is, the ability of acetate to raise the intracellular levels of citrate may be limited in (VHL-reconstituted) cells that exhibit high endogenous levels of citrate. Whatever the mechanism, the results imply that increasing the pools of intracellular citrate has a direct biochemical effect in cells with regards to their reliance on RC. Finally, we assayed the transcript and protein levels of enzymes involved in the reductive utilization of glutamine and did not observe significant differences between VHL-deficient and VHL-reconstituted UMRC2 cells ( Figures S4I and S4J ), suggesting that HIF does not promote RC by direct transactivation of these enzymes. The IDH1/IDH2 equilibrium is defined as follows: Therefore, we sought to investigate whether HIF could affect the driving force of the IDH reaction by also enhancing NADPH production. We did not observe a significant alteration of the NADP + /NADPH ratio between VHL-deficient and VHL-positive cells in the cell lysate ( Figure S4I ). Yet, we determined the ratio of the free dinucleotides using the measured ratios of suitable oxidized (α-ketoglutarate) and reduced (isocitrate/citrate) metabolites that are linked to the NADP-dependent IDH enzymes. The determined ratios ( Figure S4J ) are in close agreement with the values initially reported by the Krebs lab (Veech et al., 1969) and showed that HIF-expressing UMRC2 cells exhibit a higher NADP + / NADPH ratio. Collectively, these data strongly suggest that HIF-regulated citrate levels modulate the reductive flux to maintain adequate lipogenesis.
Reductive Carboxylation from Glutamine Is Detectable In Vivo
VHL-deficient RCC cells rely on RC for lipid synthesis, potentially suggesting that this reaction can contribute to tumor growth. Reductive carboxylation is known to occur in bacteria and has been described in brown adipose tissue (Yoo et al., 2004) but whether it occurs in vivo in other tissues of vertebrates or in actual tumors is not known. We sought to determine the activity of RC in tumors derived from VHL-deficient UMRC3 cells growing as subcutaneous xenografts in nude mice. We infused several tumor-bearing mice with [1-13 C 1 ]glutamine (see Experimental Procedures) and analyzed the citrate enrichment in tumor extracts by high-resolution 13 C nuclear magnetic resonance (NMR) spectroscopy and GC-MS (Figure 6 ). [1-13 C 1 ]glutamine will transfer carbon to citrate only through RC, so the mere detection of 13 C enrichment in citrate will indicate that this reaction is active in vivo. In order to attain maximal 13 C enrichment of citrate, we carried out a time course infusion of [1-13 C 1 ]glutamine and attained an isotopic-steady state of 13 C glutamine enrichment in the tumor ( Figure 6A ). We also analyzed the 13 C glutamine enrichment in the plasma at the earliest and latest infusion points and observed similar 13 C enrichment after 6 hr. As seen in Figure 6B , we detected 13 C enriched citrate in the tumor within 30 min, with RC accounting for 4% of citrate production after 6 hr of infusion ( Figure 6B) . Notably, the steady-state 13 C glutamine enrichment in the tumor was 30% (Figure 6A ), indicating that the reductive flux accounts for at least 12% of citrate production in VHL-deficient tumors under these experimental conditions. The kidney cortex is reported to be relatively hypoxic (Zhong et al., 1998) . Thus, we analyzed the 13 C citrate enrichment in kidney extracts in parallel and showed that RC is also active in this organ ( Figure 6B ). The steady-state 13 C enrichment of glutamine was also established in the normal kidney, but it was higher ( Figure 6B ), indicating an overall lower contribution of RC in the kidney when compared to the tumor. Despite the steady-state 13 C enrichment of the glutamine precursor, the percentage of M1 citrate appeared to increase overtime in the tumor, whereas it reached a plateau in the normal kidneys and plasma. Importantly, there was no evidence that RC appears in the tumor in a delayed fashion compared to plasma or kidney, strongly suggesting that RC occurs in the tumor xenografts. Concordant results were obtained by 13 C NMR spectroscopy ( Figures 6C and 6D ) in which 13 C enrichment was observed in tumor extracts after 6 hr of infusion, and no signal was detected in the carboxyl group region in control mice ( Figure  6C ). These results indicate that RC occurs in vivo, at least in VHL-deficient tumors.
Loss of VHL Renders RCC Cells Sensitive to Glutamine Deprivation
RCC cells engaged in RC from glutamine to produce citrate, and this reaction was active in VHL-deficient RCC xenograft tumors. We therefore hypothesized that VHL deficiency results in cell addiction to glutamine for proliferation. We treated the isogenic clones PRC3 (VHL-deficient cells) and WT8 (VHL-reconstituted cells) with the glutaminase inhibitor 968 (Wang et al., 2010a) . VHL-deficient PRC3 cells were more sensitive to treatment with 968, compared to the VHL-reconstituted WT8 cells ( Figure 7A ). To confirm that this is not only a cell-line-specific phenomenon, we also cultured UMRC2 cells in the presence of 968 or diluent control and showed selective sensitivity of VHL-deficient cells ( Figure 7B ). To test if the selective sensitivity of VHL-deficient cells to glutaminase inhibitors is linked, at least in part, to defective carbon supply, we asked whether cell proliferation could be rescued by anaplerotic substrates. Supplementing the cultured medium with a cell-permeable form of the substrate α-ketoglutarate or acetate, we rescued VHL-deficient cells from treatment with 968 ( Figure 7C ). The selective sensitivity and rescue by anaplerotic and lipogenic substrates was also corroborated in 786-O cells ( Figure 7D ). We observed a similar growth-inhibitory phenotype in VHL-deficient UMRC2 cells using a different glutaminase inhibitor (BPTES), confirming the sensitivity to glutamine deprivation under VHL-deficient conditions ( Figure  7E ). Glutamine addiction of VHL-deficient cells is not an in-vitro-only phenomenon. Systemic administration of the glutaminase inhibitor BPTES suppressed the growth of VHLdeficient UMRC3 cells as tumors in nude mice ( Figure 7F ).
In summary, our findings show that HIF is necessary and sufficient to promote RC from glutamine. By inhibiting glucose oxidation in the TCA cycle and reducing citrate levels, HIF shifts the IDH reaction toward RC to support citrate production and lipogenesis ( Figure 7G ). The reductive flux is active in vivo, fuels tumor growth, and can potentially be targeted pharmacologically. Understanding the significance of reductive glutamine metabolism in tumors may lead to metabolism-based therapeutic strategies.
DISCUSSION
Along with others, we reported that hypoxia and loss of VHL engage cells in reductive carboxylation (RC) from glutamine to support citrate and lipid synthesis (Filipp et al., 2012; Metallo et al., 2012; Wise et al., 2011) . Wise et al. (2011) suggested that inactivation of HIF in VHL-deficient cells leads to reduction of RC. These observations raise the hypothesis that HIF, which is induced by hypoxia and is constitutively active in VHL-deficient cells, mediates RC. In our current work, we provide mechanistic insights that link HIF to RC. First, we demonstrate that polyclonal reconstitution of VHL in several human VHL-deficient RCC cell lines inhibits RC and restores glucose oxidation. Second, the VHL mutational analysis demonstrates that the ability of pVHL to mitigate reductive lipogenesis is mediated by HIF and is not the outcome of previously reported, HIF-independent pVHL function(s). Third, to prove our hypothesis we showed that constitutive expression of a VHL-independent HIF mutant is sufficient to phenocopy the reductive phenotype observed in VHL-deficient cells. In addition, we showed that RC is not a mere in vitro phenomenon, but it can be detected in vivo in human tumors growing as mouse xenografts. Lastly, treatment of VHLdeficient human xenografts with glutaminase inhibitors led to suppression of their growth as tumors.
In this work, we also examined the mechanism(s) by which HIF promotes RC. It is established that hypoxic induction of HIF transactivates several enzymes involved in glucose uptake and glycolysis, including GLUT1, hexokinase, phosphofructokinase, and aldolase (Iyer et al., 1998) . In addition, HIF directly binds to the promoter of, and transactivates, PKM2, pyruvate dehydrogenase kinase 1 (PDK1) and lactate dehydrogenase A (LDHA) (Ebert et al., 1996; Firth et al., 1994; Kim et al., 2006; Luo et al., 2011; Papandreou et al., 2006) . This orchestrated upregulation of several enzymes ensures the diversion of pyruvate to lactate production. This raises the hypothesis that RC may be triggered by a deficient pyruvate oxidation in the mitochondrion and the subsequent reduction in citrate levels. Our MFA analysis indicated a significantly lower absolute pyruvate dehydrogenase (PDH) flux and net conversion of α-ketoglutarate into citrate upon HIF activation. The ATP citrate lyase flux was lower in VHL-deficient cells when compared to the VHL-positive counterparts, which supports our previous observations that de novo lipogenesis is decreased under hypoxia conditions (Metallo et al., 2012) . Indeed, HIF expression, either by loss of VHL or normoxic induction of HIF-2α P-A, reduced citrate levels. Conversely, administration of exogenous citrate or acetate in VHL-deficient cells restored the low citrate levels to the levels encountered in VHL-replete cells and inhibited RC. Exogenous administration of acetate or citrate had a mild effect in VHL-positive cells. In the case of either cell type, the magnitude of changes in RC reflected the degree of changes in intracellular citrate levels. These observations show that fluctuations in citrate levels by HIF modulate, at least in part, the flux of the reverse IDH reaction. This finding underlines the compensatory role of RC in maintaining an adequate flux for lipogenesis under HIF-activated conditions.
In addition to the role of HIF in regulating RC through citrate, we examined whether HIF directly regulates enzymes along the reductive TCA cycle pathway (see Figure 1B) . We did not observe changes in the transcript or protein levels of GLS, GDH, IDH1, IDH2, ACO1, or ATP citrate lyase between VHL-deficient and VHL-reconstituted UMRC2 cells. This is in line with previous studies that did not identify any of these enzymes as transcriptional targets of HIF-1α or HIF-2α (Mole et al., 2009; Ortiz-Barahona et al., 2010; Schödel et al., 2011; Wenger et al., 2005) . Nevertheless, it is conceivable that HIF may affect the activity of these enzymes through regulation of cofactor availability or posttranslational modification of the enzymes. For example, the reverse IDH reaction requires NADPH, as allosteric cofactor (Dalziel and Londesborough, 1968; Leonardi et al., 2012) and HIFmediated changes in NADPH levels may indirectly influence IDH activity. In our studies we did not observe increased NADPH levels in VHL-deficient cells when compared to the VHLpositive counterparts, which is in agreement with existing literature showing that HIF-1α activates NADPH oxidase and hypoxia limits NADPH production (Diebold et al., 2010; Tribble and Jones, 1990) . These data suggest that the mass-action effect of HIF toward RC is not accounted for by an increase in NADPH production. Other signaling pathways may regulate RC through NADPH availability, and the source(s) of NADPH contributing to RC in the cytosol/mitochondrion are under investigation. For example, the mitochondrial enzyme nicotinamide nucleotide transhydrogenase (NNT) transfers reducing equivalents from NADH to NADPH and has been hypothesized to contribute to RC by IDH2 (Sazanov and Jackson, 1994) . This hypothesis, although not yet experimentally tested, raises the possibility that NADPH-producing reactions may regulate the RC flux in a HIF-independent manner.
In addition, posttranslational modifications of the enzymes involved in RC may be influenced by hypoxia and/or HIF expression indirectly. For example, aconitase (ACO1) activity is reportedly regulated by hypoxia through iron-sulfur cluster modifications and phosphorylation (Chan et al., 2009; Rouault, 2006) , and acetyl-CoA is a required substrate for protein acetylation, which regulates major cellular functions including central carbon metabolism (Wang et al., 2010b; Zhao et al., 2010) . Thus, it is conceivable that HIF contributes to these modifications and therefore influences the activity of glutaminemetabolizing enzymes at the posttranslational level.
Our current work showed that HIF-2α is sufficient to induce the reductive program in RCC cells that express only the HIF-2α paralog, while mouse NEK cells appeared to use HIF-1α preferentially to promote RC. Together with the evidence that HIF-1α and HIF-2α may have opposite roles in tumor growth (Keith et al., 2011; Maranchie et al., 2002; Raval et al., 2005) , it is possible that the cellular context dictates which paralog activates RC. It is also possible that HIF-2α adopts the RC regulatory function of HIF-1α upon deletion of the latter in RCC cells. Further studies are warranted in understanding the relative role of HIF-α paralogs in regulating RC in different cell types. 
EXPERIMENTAL PROCEDURES Cell Culture and Metabolic Labeling
All cell lines were obtained from ATCC, tested for mycoplasma, and maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO-BRL) containing 10% FBS (HyClone) supplemented with penicillin-streptomycin (Invitrogen). Metabolic labeling was described before (Metallo et al., 2012) .
Cellular Metabolite Extractions and GC-MS Analysis
The method was described before (Metallo et al., 2012) . Briefly, metabolic activity was quenched with methanol (−80°C), an equal volume of water was added, and cells were collected in tubes by pipette scraping the wells. Two volumes of chloroform (−20°C) were added to each tube, extracts were vortexed and centrifuged at 11,000 RPM for 10 min at 4°C. The aqueous phase was used for polar metabolite analysis, and the chloroform phase was used for fatty acid analysis. Polar phase containing amino and organic acids was evaporated, dissolved in 2% methoxyamine hydrochloride in pyridine, derivatized by adding N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide + 1% tertbutyldimethylchlorosilane, and subjected to GC-MS analysis. Fatty acid methyl esters (FAMEs) were obtained by reacting the nonpolar phase with 2% H 2 SO 4 :methanol. After transesterification, FAMEs were isolated by adding hexane and saturated NaCl. The hexane phase was subjected to GC-MS analysis.
Metabolic Flux Analysis and Isotopomer Spectral Analysis
Intracellular fluxes and the specific contribution to lipogenic acetyl-CoA were estimated using the elementary metabolite unit (EMU) framework-based software Metran, executed in Matlab (Mathworks) as previously described (Metallo et al., 2012) .
Metabolite Analysis of Extracellular Medium
Cells were seeded at low density in basal DMEM and the spent medium was collected at the end of a 72 hr growth period and analyzed using a Yellow Springs Instruments (YSI) 7100.
Determination of NADP + /NADPH Ratios
Cellular NADP + /NADPH levels were assayed using a fluorescence-based assay according to the manufacturer's instructions (Cell Technology). NADP + /NADPH ratios were also determined employing the method developed in the Krebs lab, as described therein (Veech et al., 1969) .
Plasmids and Western Blots
Plasmids expressing HA-VHL mutants and HA-HIF-2α were purchased from Addgene. Plasmids encoding shRNA sequences targeting PDK1 and ACLY were obtained from the Broad Institute RNAi Consortium (TRC) library available at Massachusetts General Hostpital (MGH) (shRNA sequences available in the Supplemental Experimental Procedures). Proteins were extracted and immunobloted as described before (Zimmer et al., 2008) .
Animal Studies
All protocols conformed to institutional regulations. UMRC3 cells were injected subcutaneously in nu/nu mice (5 × 10 6 cells per injection). Tumor volumes were calculated as length (mm) × width 2 (mm 2 ) × 0.5. For in vivo 13 C-labeling studies, animals (n = 3) were infused with [1-13 C 1 ]glutamine for the indicated time periods as previously described (Marin-Valencia et al., 2012) .
C NMR Spectroscopy
High-resolution proton-decoupled 13 C NMR spectra of tumor extracts were obtained at 11.7 T (125.13 Hz, 25°C [pH 7.2]) in a Bruker AVANCE III 500 MHz Wide Bore NMR spectrometer using a commercial (5 mm) triple-resonance probe ( 1 H, 13 C, 2 H) optimized for direct 13 C detection.
Statistical Analysis
For MFA and ISA results, error bars represent 95% confidence intervals. In all other experiments, error bars represent SEM unless otherwise noted. Statistical significance was determined using two-tailed Student's t test. *p < 0.05, **p < 0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Figure S1 . 
